What is the value of screening for prostate cancer in the US? (Q43499958)

24 November 2017

title

What is the value of screening for prostate cancer in the US? (English)

1 reference

24 November 2017

Peter C Albertsen

1

1 reference

24 November 2017

publication date

1 November 2005

1 reference

Nature Clinical Practice Oncology

24 November 2017

published in

1 reference

24 November 2017

volume

2

1 reference

24 November 2017

issue

11

1 reference

24 November 2017

page(s)

536-537

1 reference

https://scigraph.springernature.com/pub.10.1038/ncponc0348

24 November 2017

exact match

0 references

cites work

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0348

20-year outcomes following conservative management of clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0348

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0348

Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0348

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0348

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0348

Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0348

7 January 2021

The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0348

7 January 2021

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0348

7 January 2021

Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0348

7 January 2021

Identifiers

DOI

10.1038/NCPONC0348

1 reference

Dimensions Publication ID

24 November 2017

1028135930

0 references

1 reference